New hope for Tough-to-Treat depression

NCT ID NCT06963021

Recruiting now Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding an investigational drug called NBI-1065845 to standard antidepressant medication helps people with major depression who haven't gotten enough relief from their current treatment. It will involve about 200 adults with moderate to severe depression who are still struggling despite taking antidepressants. Participants will be randomly assigned to receive either the new add-on drug or a placebo (inactive pill) for 8 weeks, while continuing their regular antidepressant, to see if it improves their depression symptoms and daily functioning.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neurocrine Clincial Site
RECRUITING

New York, New York, 10128, United States
Neurocrine Clinical Site
RECRUITING

Los Angeles, California, 90025, United States
Neurocrine Clinical Site
RECRUITING

Aurora, Colorado, 80045, United States
Neurocrine Clinical Site
RECRUITING

Cromwell, Connecticut, 06416, United States
Neurocrine Clinical Site
RECRUITING

Farmington, Connecticut, 06030, United States
Neurocrine Clinical Site
RECRUITING

Maitland, Florida, 32751, United States
Neurocrine Clinical Site
RECRUITING

Tampa, Florida, 33613, United States
Neurocrine Clinical Site
RECRUITING

Gaithersburg, Maryland, 20877, United States
Neurocrine Clinical Site
RECRUITING

Cedarhurst, New York, 11516, United States
Neurocrine Clinical Site
RECRUITING

New York, New York, 10029, United States
Neurocrine Clinical Site
RECRUITING

Alken, 3570, Belgium
Neurocrine Clinical Site
RECRUITING

Mechelen, 2800, Belgium
Neurocrine Clinical Site
RECRUITING

Oulu, 90100, Finland
Neurocrine Clinical Site
RECRUITING

Jelgava, LV-3008, Latvia
Neurocrine Clinical Site
RECRUITING

Liepāja, LV-3401, Latvia
Neurocrine Clinical Site
RECRUITING

Sigulda, LV-2150, Latvia

Conditions

Explore the condition pages connected to this study.

MAJOR DEPRESSIVE DISORDER